Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring MAPD Step Therapy Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentHealthSpringPolicy N/A

    Antidepressants, Serotonin/Norepinephrine Reuptake Inhibitors MAPD

    Customize your policy alerts

    Sign up for all healthspring policy alerts

    Know when healthspring releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization sequencing for selected Step 1 and Step 2 prescription drugs under the HealthSpring Medicare Advantage prescription benefit, including antidepressants, Cobenfy, Klisyri, metformin ER, Opipza, Ryaltris, Rytary, Spiriva Respimat, Trintellix, and Xhance.

    Policy Summary
    PayerHealthSpring
    PolicyAntidepressants, Serotonin/Norepinephrine Reuptake Inhibitors MAPD
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify qualifying Step 1 trials, including drug names, supply duration, and dates within the applicable lookback period, and submit paid-claim or physician-documented evidence.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Step-therapy groups represented
    30 days / 2 drugsStandard antidepressant requirement
    365 daysAntidepressant lookback
    30 days / bothMetformin requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Documented bypass exceptions

    Coverage Criteria

    Initial therapy for Step 2 antidepressants

    Step 2 antidepressants are covered when the applicable criteria are met.

    Qualifying pathway

    • Standard pathway: The member has tried at least two Step 1 antidepressants in the same step-therapy group.30-day supply or more for each within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Exception pathway: The member previously used and discontinued a Step 2 drug; or has suicidal ideation; or is requesting Auvelity for Alzheimer's agitation.

      Step 1 trials are not required under these exception pathways.

    Initial therapy for Cobenfy

    Cobenfy is covered when the applicable step-therapy criteria are met.

    Qualifying pathway: The member has tried one Step 1 antipsychotic in the same step-therapy group, or previously used and discontinued a Step 2 drug.Step 1 trial: 30-day supply or more within the previous 365 days

    Evidence may be a previous paid prescription claim or physician-documented use. Prior discontinued Step 2 use waives the Step 1 trial.

    Initial therapy for Klisyri

    Klisyri is covered when the qualifying topical Step 1 requirement is met.

    Required Step 1 therapy: The member has tried at least one Step 1 topical drug in the same step-therapy group.14-day supply or more within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Initial therapy for metformin ER 1000 mg osmotic tablets

    Metformin ER 1000 mg osmotic tablets are covered when both required Step 1 therapies are documented.

    Required Step 1 therapies: The member has tried both generic Glucophage XR and generic 500 mg Fortamet.30-day supply or more for each within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Metformin Step-2 coverage

    Metformin ER 1000 mg osmotic tablets are covered only when all requirements are met.

    Metformin Step-2 therapy: The member has tried both generic Glucophage XR metformin ER 500 mg or 750 mg tablets and generic 500 mg Fortamet metformin ER osmotic tablets.At least a 30-day supply of each within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Opipza Step-2 coverage

    Opipza is covered when the Step 1 requirement or the prior Step 2 use exception applies.

    Opipza eligibility: The member has tried at least one Step 1 drug in the same group, or is currently taking or previously took and discontinued a Step 2 drug.Step 1 trial: 30-day supply or more within the previous 365 days

    Step 1 options include aripiprazole, asenapine, lurasidone, olanzapine, paliperidone ER, quetiapine, risperidone, and ziprasidone. Prior Step 2 use waives the Step 1 trial.

    Ryaltris Step-2 coverage

    Ryaltris is covered only when the Step 1 requirement is met.

    Ryaltris Step-2 therapy: The member has tried fluticasone propionate nasal spray.At least a 14-day supply within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Rytary Step-2 coverage

    Rytary is covered only when the Step 1 requirement is met.

    Rytary Step-2 therapy: The member has tried at least one Step 1 carbidopa/levodopa product in the same group.At least a 30-day supply within the previous 180 days

    Qualifying products include carbidopa/levodopa, carbidopa/levodopa ER, carbidopa/levodopa ODT, and carbidopa/levodopa/entacapone. Evidence may be a previous paid prescription claim or physician-documented use.

    Spiriva Respimat coverage criteria

    Spiriva Respimat is covered when the applicable step-therapy requirement is met.

    Spiriva eligibility

    • Standard pathway: The member has tried both Anoro Ellipta and Incruse Ellipta.30-day supply or more of each within the previous 180 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Asthma exception: The patient has asthma.

      The Step 1 inhalers do not need to be tried.

    Trintellix coverage criteria and exceptions

    Trintellix is covered when the Step 1 requirement or an exception applies.

    Trintellix eligibility

    • Step 1 pathway: The member has tried one listed Step 1 antidepressant in the same step-therapy group.30-day supply or more within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Prior Step 2 use exception: The member is currently taking or previously took a Step 2 drug and discontinued its use.

      Step 1 trials are not required.

    • Suicidal ideation exception: The patient has suicidal ideation.

      Step 1 trials are not required.

    Xhance coverage criteria

    Xhance is covered when the Step 1 requirement or the nasal-polyps exception applies.

    Xhance eligibility

    • Step 1 pathway: The member has tried fluticasone propionate nasal spray.14-day supply or more within the previous 180 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Nasal-polyps exception: The patient has rhinosinusitis with nasal polyps.

      The Step 1 drug does not need to be tried.

    Cobenfy is covered when the member has tried at least one Step 1 antipsychotic in the same step-therapy group for a 30-day supply or more within the previous 365 days, supported by a paid prescription claim or physician-documented use. The Step 1 requirement may be bypassed when the member is currently taking, or previously took and discontinued, a Step 2 drug.

    Klisyri is covered when the member has tried at least one listed Step 1 topical drug in the same step-therapy group for a 14-day supply or more within the previous 180 days, supported by a paid prescription claim or physician-documented use. Klisyri is not covered when the required Step 1 therapy is not documented.

    Metformin ER 1000 mg osmotic tablets are covered only when the member has tried both generic Glucophage XR and generic 500 mg Fortamet, with a 30-day supply or more of each within the previous 180 days. Evidence may be a paid prescription claim or physician-documented use; without both qualifying Step 1 trials, the Step 2 product is not covered.

    Spiriva Respimat is covered when the member has tried both Anoro Ellipta and Incruse Ellipta for a 30-day supply or more of each within the previous 180 days, supported by a paid prescription claim or physician-documented use. Patients with asthma may bypass the Step 1 requirement.

    Trintellix is covered when the member has tried one listed Step 1 antidepressant for a 30-day supply or more within the previous 365 days, supported by a paid prescription claim or physician-documented use. The Step 1 requirement may be bypassed when the member is currently taking, or previously took and discontinued, a Step 2 drug, or when the patient has suicidal ideation.

    Xhance is covered when the member has tried fluticasone propionate nasal spray for a 14-day supply or more within the previous 180 days, supported by a paid prescription claim or physician-documented use. Patients with rhinosinusitis with nasal polyps may bypass the Step 1 requirement.

    Step-Therapy Trial Requirements

    Antidepressant Step 1 trial
    Required Step 1 drugsAt least two Step 1 antidepressants in the same step-therapy group
    Minimum supply30-day supply or more for each drug
    Lookback periodWithin the previous 365 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use
    Cobenfy Step 1 trial
    Required Step 1 drugAt least one Step 1 antipsychotic in the same step-therapy group
    Minimum supply

    Authorization, Documentation, and Denial Rules

    Step Therapy

    Antidepressant Step-2 Authorization and Denial Risk

    For Auvelity, Exxua, or Fetzima, verify that the member tried at least two qualifying Step-1 antidepressants before authorizing Step-2 therapy. Document the required trial duration, lookback period, and any applicable exception.

    • Step-1 drugs: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, and venlafaxine.
    • Step-2 drugs: Auvelity, Exxua, and Fetzima.
    • Each of at least two Step-1 drugs requires a 30-day supply or more within the previous 365 days, verified by a paid prescription claim or physician documentation.
    • Authorize without Step-1 trials when the member currently uses or previously used and discontinued a Step-2 drug; Step-1 trials are also waived for suicidal ideation, or for Auvelity requested for Alzheimer's agitation.
    • Insufficient qualifying Step-1 trials may result in denial.
    Prior Authorization

    Cobenfy Authorization and Supporting Documentation

    Policy Background

    Pharmacy step therapy sequences coverage by requiring use of designated Step 1 therapies before selected Step 2 medications. For each request, verify the required prior therapy within the applicable lookback period, including the drug name, supply duration, and dates. Evidence may be a paid prescription claim or physician documentation. The required sequence varies by product: some medications require one Step 1 trial, others require two or require both specified products, and documented exceptions may allow Step 1 to be bypassed.

    Step-Therapy Definitions

    Step 1 and Step 2 drugs
    Step 1 drugsPrerequisite therapies that must generally be tried before a Step 2 drug
    Step 2 drugsProducts that require the specified Step 1 trial before coverage
    ExceptionsA Step 2 drug may be authorized without Step 1 trials when a policy-specified exception applies

    Initial Therapy Criteria by Product

    Auvelity, Exxua, and Fetzima initial therapy criteria

    Step 2 antidepressants require the applicable Step 1 trials unless an exception applies.

    Antidepressant Step 2 eligibility

    • Standard pathway: The member has tried at least two Step 1 antidepressants in the same step-therapy group.30-day supply or more for each within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Exception pathway: The member previously used and discontinued a Step 2 drug; or has suicidal ideation; or is requesting Auvelity for Alzheimer's agitation.

      Step 1 trials are waived under these exception pathways.

    Cobenfy initial therapy and discontinued Step 2 exception

    Step-Therapy Requirements by Product

    Step 1 therapyStep 2 therapyRequirement or exception
    At least two Step 1 antidepressants in the same step-therapy group; each with a 30-day supply or more within the previous 365 daysAuvelity, Exxua, or FetzimaStep 1 trials may be waived for prior discontinued Step 2 use, suicidal ideation, or Auvelity requested for Alzheimer's agitation
    Step 1 therapyStep 2 therapyRequirement or exception
    At least one Step 1 antipsychotic in the same step-therapy group; 30-day supply or more within the previous 365 daysCobenfyStep 1 trial may be waived when the member is currently taking or previously took and discontinued a Step 2 drug
    Step 1 therapyStep 2 therapyRequirement
    At least one Step 1 topical drug; 14-day supply or more within the previous 180 daysKlisyriThe Step 1 trial is required before coverage
    Step 1 therapyStep 2 therapyRequirement
    Both generic Glucophage XR metformin ER 500 mg or 750 mg tablets and generic 500 mg Fortamet metformin ER osmotic tabletsMetformin ER 1000 mg osmotic tablets (generic Fortamet)At least a 30-day supply of each product is required
    Step 1 therapyStep 2 therapyLookback requirement
    Generic Glucophage XR and generic 500 mg FortametMetformin ER 1000 mg osmotic tabletsBoth products must have been used for a 30-day supply or more within the previous 180 days
    Step 1 therapyStep 2 therapyRequirement or exception
    At least one Step 1 antipsychotic in the aripiprazole, asenapine, lurasidone, olanzapine, paliperidone ER, quetiapine, risperidone, or ziprasidone group; 30-day supply or more within the previous 365 daysOpipzaStep 1 trial may be waived when the member is currently taking or previously took and discontinued a Step 2 drug
    Step 1 therapyStep 2 therapyRequirement
    Fluticasone propionate nasal spray; 14-day supply or more within the previous 180 daysRyaltrisThe Step 1 trial is required before coverage
    Step 1 therapyStep 2 therapyRequirement
    At least one carbidopa/levodopa, carbidopa/levodopa ER, carbidopa/levodopa ODT, or carbidopa/levodopa/entacapone product; 30-day supply or more within the previous 180 daysRytaryThe Step 1 trial is required before coverage
    Step 1 therapyStep 2 therapyRequirement or exception
    Both Anoro Ellipta and Incruse Ellipta; 30-day supply or more of each within the previous 180 daysSpiriva RespimatPatients with asthma may bypass the Step 1 requirement
    Step 1 therapyStep 2 therapyRequirement or exception
    One listed Step 1 antidepressant; 30-day supply or more within the previous 365 daysTrintellixStep 1 trial may be waived for prior discontinued Step 2 use or suicidal ideation
    Step 1 therapyStep 2 therapyRequirement or exception
    Fluticasone propionate nasal spray; 14-day supply or more within the previous 180 daysXhancePatients with rhinosinusitis with nasal polyps may bypass the Step 1 requirement
    Policy Summary
    PayerHealthSpring
    PolicyAntidepressants, Serotonin/Norepinephrine Reuptake Inhibitors MAPD
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify qualifying Step 1 trials, including drug names, supply duration, and dates within the applicable lookback period, and submit paid-claim or physician-documented evidence.
    SourceLink
    On This Page
    Coverage CriteriaStep-Therapy Trial RequirementsAuthorization, Documentation, and Denial RulesPolicy BackgroundStep-Therapy DefinitionsInitial Therapy Criteria by ProductStep-Therapy Requirements by Product
    30-day supply or more
    Lookback periodWithin the previous 365 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use
    Klisyri Step 1 trial
    Required Step 1 drugAt least one Step 1 topical drug in the same step-therapy group
    Minimum supply14-day supply or more
    Lookback periodWithin the previous 180 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use
    Metformin ER Step 1 trials
    Required Step 1 productsBoth generic Glucophage XR and generic 500 mg Fortamet
    Minimum supply30-day supply or more of each product
    Lookback periodWithin the previous 180 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use
    Anoro Ellipta/Incruse Ellipta trial
    Required Step 1 productsBoth Anoro Ellipta and Incruse Ellipta
    Minimum supply30-day supply or more of each drug
    Lookback periodWithin the previous 180 days
    ExceptionFor patients with asthma, Step 1 drugs do not need to be tried
    Step 1 antidepressant trial
    Required Step 1 drugOne Step 1 antidepressant in the same step-therapy group
    Minimum supply30-day supply or more
    Lookback periodWithin the previous 365 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use
    Fluticasone propionate trial
    Required Step 1 drugFluticasone propionate nasal spray
    Minimum supply14-day supply or more
    Lookback periodWithin the previous 180 days
    Evidence acceptedA previous paid claim under the prescription benefit or physician-documented use

    Before authorizing Cobenfy, verify one qualifying Step-1 trial or a documented prior-use exception. Supporting evidence must establish the trial or prior Step-2 use.

    • Step-1 drugs: aripiprazole, asenapine, lurasidone, olanzapine, paliperidone ER, quetiapine, risperidone, and ziprasidone.
    • Require a 30-day supply or more within the previous 365 days, evidenced by a paid prescription claim or physician documentation.
    • Authorize without a Step-1 trial when the member is currently taking or previously took and discontinued Cobenfy.
    • Cobenfy is not covered and may be denied when the qualifying Step-1 trial or exception evidence is absent.
    Step Therapy

    Klisyri Authorization and Step Therapy

    Before authorizing Klisyri, verify one qualifying Step-1 trial and retain supporting documentation. Klisyri is not covered when the required Step-1 evidence is missing.

    • Step-1 drugs: imiquimod 5% cream, imiquimod 3.75% cream, fluorouracil 5% or 2% solution, fluorouracil 5% cream, and fluorouracil 0.5% cream.
    • Require a 14-day supply or more within the previous 180 days, evidenced by a paid prescription claim or physician documentation.
    • Insufficient or undocumented Step-1 therapy may result in denial.
    Prior Authorization

    Metformin ER Authorization and Required Evidence

    Authorize metformin ER 1000 mg osmotic tablets (generic Fortamet) only after verifying both required Step-1 trials. Claims or physician documentation must establish the specified products, supply, and lookback period.

    • Step-1 therapy requires both generic Glucophage XR (metformin ER 500 mg or 750 mg tablets) and generic 500 mg Fortamet (metformin ER 500 mg osmotic tablets).
    • Each trial must be a 30-day supply or more within the previous 180 days.
    • Metformin ER Step-2 therapy is not covered when both required Step-1 trials are not documented; criteria not met may result in denial.
    • Use paid prescription claims or physician documentation as trial evidence.
    Step Therapy

    Opipza Authorization and Step-1 Requirement

    Before authorizing Opipza, verify one qualifying Step-1 trial or an eligible prior-use exception. Document the evidence supporting the trial or exception.

    • Step-1 drugs: aripiprazole, asenapine, lurasidone, olanzapine, paliperidone ER, quetiapine, risperidone, and ziprasidone.
    • Require a 30-day supply or more within the previous 365 days, evidenced by a paid prescription claim or physician documentation.
    • Authorize without a Step-1 trial when the member is currently taking or previously took and discontinued Opipza.
    • A missing Step-1 trial without an applicable exception may result in denial.
    Step Therapy

    Ryaltris Authorization and Fluticasone Trial

    Before authorizing Ryaltris, verify and document a qualifying fluticasone propionate nasal spray trial. Ryaltris is not covered when the required Step-1 evidence is absent.

    • Require fluticasone propionate nasal spray for a 14-day supply or more within the previous 180 days.
    • Evidence may be a paid prescription claim or physician documentation.
    • A missing or insufficient fluticasone trial may result in denial.
    Step Therapy

    Rytary Authorization and Step-1 Requirement

    Before authorizing Rytary, verify one qualifying carbidopa/levodopa Step-1 trial and retain supporting evidence. Rytary is not covered when the required trial is missing.

    • Step-1 products: carbidopa/levodopa, carbidopa/levodopa ER, carbidopa/levodopa ODT, and carbidopa/levodopa/entacapone.
    • Require a 30-day supply or more within the previous 180 days, evidenced by a paid prescription claim or physician documentation.
    • A missing Step-1 trial may result in denial.
    Step Therapy

    Spiriva Respimat Authorization and Denial Risk

    Before authorizing Spiriva Respimat, verify both required Step-1 inhaler trials and document the evidence. The asthma exception waives the Step-1 requirement.

    • Step-1 drugs: both Anoro Ellipta and Incruse Ellipta.
    • Each trial requires a 30-day supply or more within the previous 180 days, evidenced by paid prescription claims or physician documentation.
    • Spiriva Respimat is not covered when both Step-1 trials are not documented, unless the patient has asthma.
    • Failure to document both required trials may result in denial.
    Step Therapy

    Trintellix Authorization and Step Therapy

    Before authorizing Trintellix, verify one qualifying Step-1 antidepressant trial or an applicable exception. Supporting documentation must establish the trial or prior Step-2 use.

    • Step-1 drugs: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine, and vilazodone.
    • Require a 30-day supply or more within the previous 365 days, evidenced by a paid prescription claim or physician documentation.
    • Authorize without a Step-1 trial when the member currently uses or previously used and discontinued a Step-2 drug, or when the member has suicidal ideation.
    • Trintellix is not covered and may be denied when the Step-1 trial or exception is not documented.
    Step Therapy

    Xhance Authorization and Fluticasone Trial

    Before authorizing Xhance, verify and document a qualifying fluticasone propionate nasal spray trial or the applicable clinical exception. Xhance is not covered when the required evidence is absent.

    • Require fluticasone propionate nasal spray for a 14-day supply or more within the previous 180 days, evidenced by a paid prescription claim or physician documentation.
    • For rhinosinusitis with nasal polyps, the Step-1 trial is not required.
    • A missing fluticasone trial without the exception may result in denial.

    Cobenfy requires a qualifying Step 1 trial unless prior discontinued Step 2 use is documented.

    Cobenfy eligibility

    • Step 1 pathway: The member has tried one Step 1 antipsychotic in the same step-therapy group.30-day supply or more within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Discontinued Step 2 exception: The member previously used a Step 2 drug and discontinued its use.

      The Step 1 trial is not required.

    Klisyri initial therapy criteria

    Klisyri requires a qualifying topical Step 1 trial.

    Klisyri eligibility: The member has tried at least one listed Step 1 topical drug in the same step-therapy group.14-day supply or more within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use. Listed options include imiquimod and fluorouracil products.

    Metformin ER 1000 mg osmotic tablet initial therapy

    Metformin ER 1000 mg osmotic tablets require both specified Step 1 products.

    Metformin ER eligibility: The member has tried both generic Glucophage XR and generic 500 mg Fortamet.30-day supply or more for each within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Metformin Step therapy criteria

    The metformin ER 1000 mg osmotic Step 2 drug requires both specified Step 1 trials.

    Required metformin Step 1 drugs: The member has tried generic Glucophage XR metformin ER 500 mg or 750 mg tablets and generic 500 mg Fortamet metformin ER osmotic tablets.At least 30 days of each within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Opipza Step therapy and prior Step 2 exception

    Opipza requires one Step 1 antipsychotic trial unless the prior Step 2 use exception applies.

    Opipza Step 1 requirement or exception

    • Step 1 pathway: The member has tried at least one of aripiprazole, asenapine, lurasidone, olanzapine, paliperidone ER, quetiapine, risperidone, or ziprasidone.30-day supply or more within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Prior Step 2 exception: The member is currently taking or previously took and discontinued a Step 2 drug.

      The Step 1 trial is not required.

    Ryaltris Step therapy

    Ryaltris requires a trial of fluticasone propionate nasal spray.

    Ryaltris Step 1 drug: The member has tried fluticasone propionate nasal spray.At least 14 days within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Rytary Step therapy

    Rytary requires a trial of at least one carbidopa/levodopa Step 1 product.

    Rytary Step 1 drugs: The member has tried at least one carbidopa/levodopa, carbidopa/levodopa ER, carbidopa/levodopa ODT, or carbidopa/levodopa/entacapone product.At least 30 days within the previous 180 days

    Evidence may be a previous paid prescription claim or physician-documented use.

    Spiriva Respimat initial therapy and asthma exception

    Initial therapy for Spiriva Respimat requires prior use of both Step 1 inhalers unless the asthma exception applies.

    Spiriva eligibility

    • Standard pathway: The member has tried both Anoro Ellipta and Incruse Ellipta.30-day supply or more of each within the previous 180 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Asthma exception: The patient has asthma.

      The Step 1 inhalers do not need to be tried.

    Trintellix initial therapy and exceptions

    Initial therapy for Trintellix requires prior use of one Step 1 antidepressant unless an exception applies.

    Trintellix eligibility

    • Step 1 pathway: The member has tried one of bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine, or vilazodone.30-day supply or more within the previous 365 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Prior Step 2 use exception: The member is currently taking or previously took a Step 2 drug and discontinued its use.

      The Step 1 trial is not required.

    • Suicidal ideation exception: The patient has suicidal ideation.

      The Step 1 trial is not required.

    Xhance initial therapy and nasal-polyps exception

    Initial therapy for Xhance requires prior use of fluticasone propionate nasal spray unless the nasal-polyps exception applies.

    Xhance eligibility

    • Step 1 pathway: The member has tried fluticasone propionate nasal spray.14-day supply or more within the previous 180 days

      Evidence may be a previous paid prescription claim or physician-documented use.

    • Nasal-polyps exception: The patient has rhinosinusitis with nasal polyps.

      The Step 1 trial is not required.